The 11 most recent market catalysts affecting $PGEN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 65
Citizens Raises Precigen Price Target Following Q3 Results
Citizens, an investment firm, increased its price target for Precigen (PGEN) shares from $11 to $12 while reiterating its 'Market Outperform' rating. This positive analyst action s…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 85
Precigen Reports Third Quarter 2026 Financial Results
Precigen reported strong Q3 2026 financial results, highlighting significant sequential revenue growth for its commercial-stage therapy, PAPZIMEOS, and achieving positive cash flow…
Nov 2, 2026
Corporate Catalyst
Bearish
Impact 75
Precigen Shares Decline Following Approval of Rival RRP Treatment
Precigen's stock experienced a sharp decline following the FDA approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis (RRP). This development introduce…
Oct 28, 2026
Corporate Catalyst
Neutral
Impact 55
Precigen to Announce Third Quarter 2026 Financial Results on November 4
Precigen, Inc. (PGEN) filed an 8-K to announce the date for its third-quarter 2026 financial results and business update, scheduled for November 4, 2026. This filing itself is a pr…
Sep 25, 2026
Corporate Catalyst
Neutral
Impact 65
B. Riley Securities Initiates Coverage On Precigen with Buy Rating, Announces Price Target of $12
B. Riley Securities analyst Yuan Zhi has initiated coverage on Precigen (PGEN) with a 'Buy' rating and a $12 price target. This is a significant event for Precigen as new analyst c…
Sep 21, 2026
Corporate Catalyst
Bullish
Impact 75
Precigen Says FDA Granted Platform Technology Designation To AdenoVerse Immunotherapy Platform
The FDA's Platform Technology Designation for Precigen's AdenoVerse Immunotherapy Platform is a strong positive signal. This designation can streamline the regulatory review proces…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 75
Precigen shares are trading higher after the company reported better-than-expected Q2 financial results. Also, HC Wainwright raised its price target on the stock from $14 to $18.
This headline indicates a strong positive catalyst for Precigen (PGEN). Better-than-expected earnings demonstrate operational strength and potentially improved profitability, while…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Precigen, Raises Price Target to $18
HC Wainwright & Co. maintaining a 'Buy' rating and raising the price target for Precigen from $14 to $18 is a positive signal for the company. This analyst action suggests increase…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Precigen shares are trading higher after the company reported better-than-expected Q2 financial results.
This headline represents a significant corporate catalyst for Precigen. Better-than-expected financial results often lead to increased investor confidence, driving up share prices …
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Precigen Q2 EPS $0.05 Beats $(0.01) Estimate, Sales $54.978M Beat $27.833M Estimate
This headline represents a significant positive corporate catalyst for Precigen (PGEN). Beating both EPS and sales estimates by a substantial margin indicates strong execution and …
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $14 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating and a $14 price target for Precigen (PGEN). This action signifies that the analyst's positive outlo…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.